Priya Chandra

Pharmacokinetics and Pharmacodynamics of LCZ696, a Novel Dual‐Acting Angiotensin Receptor—Neprilysin Inhibitor (ARNi)

Jessie Gu, Adele Noè, Priya Chandra et al. · The Journal of Clinical Pharmacology · 2009 · 502 citations

Medicine, Pharmacokinetics, Pharmacology +17

Pharmacodynamic and Pharmacokinetic Profiles of Sacubitril/Valsartan (<scp>LCZ</scp>696) in Patients with Heart Failure and Reduced Ejection Fraction

Zhanna Kobalava, Yu. V. Kotovskaya, Diego Albrecht et al. · Cardiovascular Therapeutics · 2016 · 80 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17

Inhibition of Complement Factor 3 in Geographic Atrophy with NGM621: Phase 1 Dose-Escalation Study Results

Charles C. Wykoff, Vrinda Hershberger, David Eichenbaum et al. · American Journal of Ophthalmology · 2021 · 26 citations

Medicine, Neurology, Ophthalmology +17

A Phase 2 Open-Label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous ANX005 in Patients with, or at Risk of, Manifest Huntington’s Disease (HD) (S32.009)

Rajeev Kumar, Daniel O. Claassen, Ann Mongan et al. · Neurology · 2023 · 18 citations

Pharmacy, Pharmacokinetics, Pharmacology +15

[O2–17–03]: A PHASE I STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF RO7105705 IN HEALTHY VOLUNTEERS AND PATIENTS WITH MILD‐TO‐MODERATE AD

Geoffrey A. Kerchner, Gai Ayalon, Flávia Brunstein et al. · Alzheimer s & Dementia · 2017 · 12 citations

Life Sciences, Neurology, Neuroscience +17